The UK and US have finalized a significant trade agreement that will guarantee zero levies on UK pharmaceutical exports entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to boost spending on drugs through the public health system. This move secures that tariffs on these vital products will remain at zero for a duration of the next three years.
This agreement comes after previous threats to dramatically increase duties on patented drug products, with increases discussed reaching 100%.
"This agreement between the Britain bolsters the worldwide climate for innovative medicines and introduces much-needed equity to transatlantic drug exports," an announcement said.
Economic Impact
Medicines constitute one of the UK's most significant goods shipped to the America, which is clearly the biggest market for major British pharmaceutical firms.
Statistics reveal that in the year leading up to last September, the UK shipped pharmaceutical products worth billions to the US. This figure made up nearly one-fifth of all goods exports in that timeframe.
"This deal safeguards employment, increases capital expenditure and facilitates the UK to emerge as a international leader for life sciences," a minister commented.
Key UK Commitments
The agreement includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must return to the NHS to control costs will be capped at fifteen percent. Previously, repayments were more than twenty percent.
Broader Context
The deal takes place against a ongoing tension between the drug companies and the British authorities over drug pricing and NHS adoption.
This friction were intensified by claims that US consumers were charged a premium for the same drugs than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been paused or abandoned, while substantial funding commitments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had decreased as a share of its total funding over the last ten years.
